
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
The infection rate was cut in half for the men with the InhibiZone antibiotic covering (1.36% vs. 2.41% in those receiving the untreated prosthesis).





